Ilyang Pharmaceutical Non-Registered Executive Jeong Yeon-chan Acquires 1,050 Shares via Open Market, Stake Remains 0.01%... Limited Impact on Shareholder Value
Ilyang Pharmaceutical non-registered executive Jeong Yeon-chan acquired an additional 1,050 shares through open market purchase on May 28, 2026, at an average price of KRW 9,610, increasing his holdings from 70 to 1,120 shares, but the stake remains unchanged at 0.01%.
This purchase is negligible relative to the total outstanding shares of 19,530,744, causing no material change to the company's financial structure or control.
The purchase price (KRW 9,610) is 3.2% higher than the closing price on the base date (KRW 9,310), indicating a slight premium, but the total amount (approx. KRW 10.1 million) is too small to be interpreted as a strong undervaluation signal.
[AI Comprehensive Analysis]This disclosure is a minor insider share purchase with no direct impact on corporate value or shareholder return policies. It should be considered a neutral event; investors should focus on larger stake changes or share buybacks/cancellations.
KOSPI Filing Information
Filing: Report on Ownership of Specific Securities by Executives and Major Shareholders